Scioto Biosciences has leveraged EGC's partnership to secure over $2.5 million in NIH funding, driving advancements in probiotic treatments for conditions like necrotizing enterocolitis and autism, and attracting a $26.5 million Series B investment.

Client: Scioto Biosciences  .  Location: Indianapolis, Indiana
Sector: BioTech  .  Link:

Scioto Biosciences has received over $2.5 million in non-dilutive funding from NIH to develop its novel probiotic platform that has the potential to serve as a treatment for a range of diseases that have implicated gut microbiome alteration as the cause.

Scioto Biosciences was founded in 2017 to facilitate the development of novel microbiome therapeutics that originated from the Research Institute at Nationwide Children’s Hospital (RINCH). Through a partnership with EGC, Scioto Biosciences successfully secured NIH Phase II SBIR funding to apply the technology to treating necrotizing enterocolitis (NEC), a disease that leads to the breakdown of the intestine and it is the most common gastrointestinal (GI) emergency for premature infants.

The company subsequently expanded development efforts into other indications, namely autism spectrum disorder. In 2023, Scioto Biosciences published positive Phase Ib results for autism and has continued clinical development of their technology.

Scioto Biosciences’ early success has led to a $26.5 million series B investment from Genome & Company, a clinical-stage biotechnology company based in Seongnam, Republic of Korea that focuses on discovering and developing the next waves of innovative therapeutics in immuno-oncology through diverse modalities of microbiome, novel target immune checkpoint inhibitors and fusion proteins to fulfill the unmet needs of cancer patients.